Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB186748 in solid tumor, pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) (6 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities up to 28 days, Treatment-emergent Adverse Events and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
INCB186748
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06818812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818812.